UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P1010 Guselkumab improves abdominal pain and bowel urgency symptoms in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1825-i1826

2024

Volltextzugriff (PDF)

Management of Patient with Simultaneous Overt Gastrointestinal Bleeding and Myocardial Infarction with ST-Segment Elevation - Priority Endoscopy

Vascular health and risk management, 2021-01, Vol.17, p.123-133

2021

Volltextzugriff (PDF)

P902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1653-i1654

2024

Volltextzugriff (PDF)

P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1737-i1738

2024

Volltextzugriff (PDF)

DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i92-i93

2024

Volltextzugriff (PDF)

P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i716-i717

2023

Volltextzugriff (PDF)

DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD)

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i161-i162

2023

Volltextzugriff (PDF)

P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i623-i624

2023

Volltextzugriff (PDF)

DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S108-S110

2020

Volltextzugriff (PDF)

P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S401-S402

2020

Volltextzugriff (PDF)

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2017-07, Vol.390 (10090), p.135-144

2017

Volltextzugriff (PDF)

P746 Clinical characteristic of Crohn's disease patients in Polish population

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S464-S464

2017

Volltextzugriff (PDF)

Study quality of life after drinking cure of humus water in patients with alcohol dependence

Boletin Sociedad Española Hidrologia Medica, 2018, Vol.33 (S1), p.149-150

2018

Volltextzugriff (PDF)

OP023 Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S13-S14

2017

Volltextzugriff (PDF)

DOP075 Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's disease

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S70-S71

2017

Volltextzugriff (PDF)

P103 Usefulness of fluorescence spectroscopy in the diagnosis of inflammatory bowel diseases

Journal of Crohn's and colitis, 2014-02, Vol.8, p.S105-S105

2014

Volltextzugriff (PDF)

Relationship between results of electrocardiographic exercise tests and intraesophageal pH in men with atypical chest pain

Polskie archiwum medycyny wewne̦trznej, 2000-03, Vol.103 (3-4), p.133

2000

Volltextzugriff (PDF)

P421 Real-world effectiveness and safety of vedolizumab induction therapy for Crohn’s disease in Poland – a prospective, observational POLONEZ II study considering patients reported outcomes

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i550-i551

2023

Volltextzugriff (PDF)

P36 Pantoprazole 20???mg is as effective as esomeprazole 20???mg in maintaining esophageal healing in erosive GERD

Journal of clinical gastroenterology, 2006-09, Vol.40 (Supplement 4), p.S205

2006

Volltextzugriff (PDF)

P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S381-S381

2020

Volltextzugriff (PDF)

NALTREXONE EXERTS A FAVOURABLE EFFECT ON PLASMA LIPIDS IN ABSTINENT PATIENTS WITH ALCOHOL DEPENDENCE

Alcohol and alcoholism (Oxford), 2000-01, Vol.35 (1), p.91-97

2000

Volltextzugriff (PDF)

LIPOPROTEIN(a) IN ALCOHOL-DEPENDENT MALE PATIENTS DURING A SIX-MONTH ABSTINENCE PERIOD

Alcohol and alcoholism (Oxford), 2003-03, Vol.38 (2), p.157-162

2003

Volltextzugriff (PDF)

Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole

Medical science monitor, 2004-10, Vol.10 (10), p.PI115-PI118

2004

Volltextzugriff (PDF)

DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S056-S057

2019

Volltextzugriff (PDF)

DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S058-S059

2019

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(57)
Texte
(1)

Sprache

Englisch
(50)
Polnisch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(24)
Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Male
(16)
Middle Aged
(13)
Adult
(12)
Female
(11)
Amoeba Proteus
(6)
Animals
(6)
Cell Biology
(6)
Cytoskeleton
(6)
Aged
(5)
Adolescent
(4)
Biochemistry & Molecular Biology
(4)
Medicine, Research & Experimental
(4)
Plant Sciences
(4)
Proteins
(4)
Research & Experimental Medicine
(4)
2-Pyridinylmethylsulfinylbenzimidazoles
(3)
Actins - Metabolism
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

P1010 Guselkumab improves abdominal pain and bowel urgency symptoms in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study

Management of Patient with Simultaneous Overt Gastrointestinal Bleeding and Myocardial Infarction with ST-Segment Elevation - Priority Endoscopy

P902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study

P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study

DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial

P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis

DOP86 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD)

P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study

DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study

P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial

P746 Clinical characteristic of Crohn's disease patients in Polish population

Study quality of life after drinking cure of humus water in patients with alcohol dependence

OP023 Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study

DOP075 Efficacy of filgotinib, a selective JAK1 inhibitor, is independent of prior anti-TNF exposure: subgroup analysis of the phase 2 FITZROY study in moderate-to-severe Crohn's disease

P103 Usefulness of fluorescence spectroscopy in the diagnosis of inflammatory bowel diseases

Relationship between results of electrocardiographic exercise tests and intraesophageal pH in men with atypical chest pain

P421 Real-world effectiveness and safety of vedolizumab induction therapy for Crohn’s disease in Poland – a prospective, observational POLONEZ II study considering patients reported outcomes

P36 Pantoprazole 20???mg is as effective as esomeprazole 20???mg in maintaining esophageal healing in erosive GERD

P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology

NALTREXONE EXERTS A FAVOURABLE EFFECT ON PLASMA LIPIDS IN ABSTINENT PATIENTS WITH ALCOHOL DEPENDENCE

LIPOPROTEIN(a) IN ALCOHOL-DEPENDENT MALE PATIENTS DURING A SIX-MONTH ABSTINENCE PERIOD

Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole

DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II

DOP51 Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis

Suchergebnisse filtern